Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients von Bjerregaard, J.K, Mortensen, M.B, Schønnemann, K.R, Pfeiffer, P

Volltext

Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer von Schønnemann, K.R, Yilmaz, M, Bjerregaard, J.K, Nielsen, K.M, Pfeiffer, P

Volltext

Clinical utility of plasma cell-free DNA in patients with pancreatic cancer von Chen, I., Wind, K.L., Dehlendorff, C., Sørensen, B.S., Vittrup, B.V., Johansen, A., Pfeiffer, P., Bjerregaard, J.K., Bojesen, S.E., Nielsen, S.E., Holländer, N.H., Yilmaz, M.K., Rasmussen, L.S., Pallisgaard, N., Johansen, J.S., Spindler, K.-L.G.

Volltext

Clinical utility of serum type III collagen in patients with pancreatic carcinoma von Chen, I., Willumsen, N., Dehlendorff, C., Johansen, A., Vittrup, B.V., Krüger, M., Pfeiffer, P., Bjerregaard, J.K., Bojesen, S.E., Nielsen, S.E., Holländer, N.H., Yilmaz, M.K., Rasmussen, L.S., Karsdal, M., Johansen, J.S.

Volltext

2309 Phase I dose-finding study of S-1 in combination with docetaxel and oxaliplatin (DOS2w) administered every second week in patients with advanced gastro-esophageal cancer von Schoennemann, K.R, Vestermark, L.W, Jensen A, H, Bjerregaard K, J, Krogh, M, Qvortrup, C, Tarpgaard S, L, Ejlsmark, M.W, Pfeiffer, P

Volltext

MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer von Schultz, Nicolai A, Dehlendorff, Christian, Jensen, Benny V, Bjerregaard, Jon K, Nielsen, Kaspar R, Bojesen, Stig E, Calatayud, Dan, Nielsen, Svend E, Yilmaz, Mette, Holländer, Niels Henrik, Andersen, Klaus K, Johansen, Julia S

Volltext

550PUpdated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type met... von Pfeiffer, P, Bjerregaard, J K, Qvortrup, C, Sorbye, H, Glimelius, B, Kersten, C

Volltext

796PRandomised phase II trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma (S... von Petersen, P C, Noergaard Petersen, L, Vogelius, I R, Bjerregaard, J K, Baeksgaard, L

Volltext

Chemotherapy for patients with non-resectable pancreatic cancer with additional chemo-radiotherapy for patients with potentially resectable tumours: Final results von Pfeiffer, P., Ladekarl, M., Mortensen, M.B., Fromm, A.-L., Bjerregaard, J.K.

Volltext

Temozolimide and capecitabine in patients with refractory KRAS wildtype metastatic colorectal cancer. A phase II trial von Qvortrup, C., Keldsen, N., Andersen, F., Jensen, H.A., Krogh, M., Vestermark, L.W., Bjerregaard, J.K., Pfeiffer, P.

Volltext

Multidisciplinary team conferences promote treatment according to guidelines in rectal cancer von Brännström, Fredrik, Bjerregaard, Jon K, Winbladh, Anders, Nilbert, Mef, Revhaug, Arthur, Wagenius, Gunnar, Mörner, Malin

Volltext

752PClinical utility of serum type III collagen in patients with pancreatic carcinoma von Chen, I, Willumsen, N, Dehlendorff, C, Johansen, A, Vittrup, B V, Krüger, M, Pfeiffer, P, Bjerregaard, J K, Bojesen, S E, Nielsen, S E, Holländer, N H, Yilmaz, M K, Rasmussen, L S, Karsdal, M, Johansen, J S

Volltext

699PPre-treatment serum 25-hydroxyvitamin D levels and survival in a Danish cohort of patients with pancreatic cancer von Rasmussen, L S, Yilmaz, M, Falkmer, U G, Poulsen, L Ø, Bojesen, S E, Vittrup Jensen, B, Johansen, A Z, Chen, I M, Hansen, C P, Hasselby, J P, Pfeiffer, P, Bjerregaard, J K, Nielsen, S E, Andersen, F Z, Holländer, N H, Bøgsted, M, Johansen, J S

Volltext

715PClinical utility of plasma cell-free DNA in patients with pancreatic cancer von Chen, I, Wind, K L, Dehlendorff, C, Sørensen, B S, Vittrup, B V, Johansen, A, Pfeiffer, P, Bjerregaard, J K, Bojesen, S E, Nielsen, S E, Holländer, N H, Yilmaz, M K, Rasmussen, L S, Pallisgaard, N, Johansen, J S, Spindler, K-L G

Volltext

Prognostic and diagnostic value of serum hyaluronan in patients with pancreatic carcinoma von Chen, Inna, Dehlendorff, Christian, Johansen, Astrid Zedlitz, Jensen, Benny Vittrup, Krüger, Mie Barthold, Pfeiffer, Per, Bjerregaard, Jon Kroll, Bojesen, Stig Egil, Nielsen, Svend Erik, Hollander, Niels Henrik, Yilmaz, Mette, Rasmussen, Louise Skau, Johansen, Julia S.

Volltext

Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation... von Pfeiffer, Per, Sorbye, Hafdan, Qvortrup, Camilla, Karlberg, Mia, Kersten, Christian, Vistisen, Kirsten, Lindh, Birgitta, Bjerregaard, Jon Kroll, Glimelius, Bengt

Volltext

Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer von Bjerregaard, J. K., Schønnemann, K. R., Jensen, H. A., Vestermark, L. W., Hansen, T. P., Pfeiffer, P.

Volltext

Addition of bevacizumab or sunitinib to biweekly cetuximab and irinotecan as salvage therapy in patients with metastatic colorectal cancer after failure to CetIri von Pfeiffer, P., Joergensen, T. L., Jensen, B. V., Qvortrup, C., Skougaard, K., Bjerregaard, J. K., Hansen, T. P., Høgdal, E., Nielsen, D.

Volltext

Treatment of locally advanced pancreatic cancer with concurrent uftoral and radiotherapy. Results from 64 patients treated from 2001–2005 von Bjerregaard, J. K., Schønnemann, K. R., Jensen, H. A., Mortensen, M. B., Hansen, T. P., Pfeiffer, P.

Volltext

Simplification of cetuximab (Cet) administration: double dose every second week as a 60 minute infusion von Pfeiffer, P., Bjerregaard, J. K., Qvortrup, C., Jensen, B. V., Yilmaz, M., Nielsen, D.

Volltext